Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matrixx Prompts Supreme Court To Consider What Firms Must Disclose

This article was originally published in The Tan Sheet

Executive Summary

A class action suit against Zicam Cold Remedy maker Matrixx Initiatives heads to the Supreme Court, in a case that could affect the number of securities actions brought against pharma companies
Advertisement

Related Content

Search For Balance Drives Supreme Court Debate In Matrixx Case
Search For Balance Drives Supreme Court Debate In Matrixx Case
Search For Balance Drives Supreme Court Debate In Matrixx Case
Trade Groups Back Matrixx On AER Disclosure In Supreme Court Case
Zicam Maker Matrixx' Sales Plummet While Legal Costs Climb
Research Indicates Link Between Zinc Nasal Swabs, Loss of Smell
Matrixx Projects Profit, But Zicam Litigation "Storm Clouds" Could Still Rain
Matrixx Initiatives Files Suit Against FDA On Unanswered FOIA Grounds
Court Revives Zicam Complaint, But Says Disclosure Remains Case-by-Case
Court Revives Zicam Complaint, But Says Disclosure Remains Case-by-Case

Topics

Advertisement
UsernamePublicRestriction

Register

PS104228

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel